Tiziana Life Sciences Email Format

Biotechnology ResearchEngland, United Kingdom2-10 Employees

Tiziana Life Sciences is a small biotechnology company focused on transformative technologies that enable alternative routes for immunotherapy. Its lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody. Based in London, United Kingdom, the company operates within the biotechnology research sector and aims to advance immunomodulation therapies. The work centers on developing approaches to modulate the immune system in diseases where such modulation could be beneficial.

In recent developments, a late-breaking poster detailing a Phase 2a study of intranasal foralumab in Multiple System Atrophy was accepted for presentation at the 7th World Parkinson Congress in 2026. This indicates ongoing clinical exploration of its immunomodulatory approach in neurodegenerative conditions.

Sign up for free to view info

Company overview Employee directory